Achillion Pharmaceuticals has reported positive interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab … more
Separately, Achillion has receieved a patent forACH-5548, its next-generation orally administered complement factor D small molecule inhibitor product candidate … more